Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CytomX Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
CytomX Therapeutics Raises USD70 Million in Series D Venture Financing 13
CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 15
CytomX Therapeutics Raises US$1.2 Million In Series B-1 Financing 16
Cytomx Therapeutics Raises Additional US$11 Million In Series B Financing 17
Partnerships 19
Amgen and CytomX Therapeutics Enter into Co-Development Agreement 19
Applied BioMath to Enter into Agreement with CytomX Therapeutics 20
CytomX Therapeutics Enters into Agreement with University of Texas M. D. Anderson Cancer Center 21
CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 22
Licensing Agreements 24
AbbVie Enters into Licensing Agreement with CytomX Therapeutics for CD71 24
AbbVie Enters into Licensing Agreement with CytomX Therapeutics 26
CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 28
Bristol-Myers Squibb Extends Licensing Agreement with CytomX Therapeutics 29
Equity Offering 31
CytomX Therapeutics Raises USD125 Million in Public Offering of Shares 31
CytomX Therapeutics Files Registration Statement for Public Offering of Shares 33
CytomX Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 34
CytomX Therapeutics Raises USD92 Million in IPO 35
CytomX Therapeutics Raises USD3.5 Million in Private Placement of Preferred Stock 37
CytomX Therapeutics Raises USD1.4 Million in Private Placement of Preferred Stock 38
CytomX Therapeutics Raises USD0.5 Million in Private Placement of Preferred Stock 39
CytomX Therapeutics Raises USD8.4 Million in Private Placement of Preferred Stock 40
CytomX Therapeutics Inc – Key Competitors 41
CytomX Therapeutics Inc – Key Employees 42
CytomX Therapeutics Inc – Locations And Subsidiaries 43
Head Office 43
Recent Developments 44
Financial Announcements 44
Aug 08, 2018: CytomX Therapeutics announces second quarter 2018 financial results 44
May 09, 2018: CytomX Therapeutics Announces First Quarter 2018 Financial Results 46
Mar 07, 2018: CytomX Therapeutics Announces Full-Year 2017 Financial Results and Provides Operational Update 48
Nov 07, 2017: CytomX Announces Third Quarter 2017 Financial Results and Operational Progress 50
Aug 07, 2017: CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call 53
May 05, 2017: CytomX Announces First Quarter 2017 Financial Results 55
Mar 02, 2017: CytomX Announces Full-Year 2016 Financial Results 56
Corporate Communications 57
Dec 18, 2017: CytomX Therapeutics Added to NASDAQ Biotechnology Index 57
Oct 24, 2017: CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to Board of Directors 58
May 15, 2017: CytomX Announces Management Team Changes 59
Mar 30, 2017: CytomX Therapeutics Appoints Marion McCourt to Board of Directors 60
Product News 61
09/08/2017: CytomX Announces Poster Presentation On CX-072 At European Society for Medical Oncology Annual Meeting 61
09/08/2017: CytomX Therapeutics To Present Poster On CX-2009 At European Society for Medical Oncology Annual Meeting 62
06/29/2017: CytomX Achieves Development Milestone in Strategic Oncology Collaboration with AbbVie for CD71-Targeting Probody Drug Conjugate 63
06/28/2017: CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-CX-2009 Trial 64
06/04/2018: CytomX Therapeutics Presents Preliminary Clinical Proof-of-Concept Data from Probody Platform and CX-072 at 2018 ASCO Annual Meeting 65
06/01/2018: CytomX Announces Conference Call and Webcast to Review PROCLAIM-072 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 67
05/17/2017: CytomX Announces Upcoming Poster Presentation at American Society for Clinical Oncology Annual Meeting 68
05/16/2018: CytomX Therapeutics Announces Presentations at 2018 ASCO Annual Meeting 69
02/02/2017: CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial 71
Product Approvals 72
May 22, 2018: CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-2029, a CD71-Directed Probody Therapeutic 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CytomX Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
CytomX Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
CytomX Therapeutics Raises USD70 Million in Series D Venture Financing 13
CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 15
CytomX Therapeutics Raises US$1.2 Million In Series B-1 Financing 16
Cytomx Therapeutics Raises Additional US$11 Million In Series B Financing 17
Amgen and CytomX Therapeutics Enter into Co-Development Agreement 19
Applied BioMath to Enter into Agreement with CytomX Therapeutics 20
CytomX Therapeutics Enters into Agreement with University of Texas M. D. Anderson Cancer Center 21
CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 22
AbbVie Enters into Licensing Agreement with CytomX Therapeutics for CD71 24
AbbVie Enters into Licensing Agreement with CytomX Therapeutics 26
CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 28
Bristol-Myers Squibb Extends Licensing Agreement with CytomX Therapeutics 29
CytomX Therapeutics Raises USD125 Million in Public Offering of Shares 31
CytomX Therapeutics Files Registration Statement for Public Offering of Shares 33
CytomX Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 34
CytomX Therapeutics Raises USD92 Million in IPO 35
CytomX Therapeutics Raises USD3.5 Million in Private Placement of Preferred Stock 37
CytomX Therapeutics Raises USD1.4 Million in Private Placement of Preferred Stock 38
CytomX Therapeutics Raises USD0.5 Million in Private Placement of Preferred Stock 39
CytomX Therapeutics Raises USD8.4 Million in Private Placement of Preferred Stock 40
CytomX Therapeutics Inc, Key Competitors 41
CytomX Therapeutics Inc, Key Employees 42
List of Figures
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CytomX Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CytomX Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10